A Trial of Lopinavir-Ritonavir in Covid-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.Canadian respiratory journal · 2020
   Pooled it
2. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.Current topics in medicinal chemistry · 2024
   Review
3. Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.The Journal of infection · 2021
   Article
4. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.Trials · 2021
   Article
5. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.European journal of clinical pharmacology · 2021
   Article
6. An integrative look at SARS‑CoV‑2 (Review).International journal of molecular medicine · 2021
   Review
7. Dissecting the interaction between COVID-19 and diabetes mellitus.Journal of diabetes investigation · 2020
   Review
8. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020
   Article
9. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.Frontiers in immunology · 2020
   Review
10. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.Frontiers in pharmacology · 2020
    Review

Corrections and comments

• Commented on by
  A Trial of Lopinavir-Ritonavir in Covid-19. Reply.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as